Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
The CoVIg-19 Plasma Alliance, a plasma industry collaboration recently launched for the development of a plasma-derived hyperimmune globulin therapy for COVID-19, has expanded its list of membership from 6 to 10, partners said on May 7. They aim for the…
To read the full story
Related Article
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
- Takeda, CSL, Other Firms Join Hands to Develop Unbranded Immunoglobulin for COVID-19
April 7, 2020
- Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
March 5, 2020
BUSINESS
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
- Personal iPSC Service to Launch with Production Cost in the 10-Million-Yen Range
March 17, 2026
- Olumiant Gains Oral Suspension Formulation in Japan
March 17, 2026
- BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…